Last 7 days
13.8%
Last 30 days
11.4%
Last 90 days
16.9%
Trailing 12 Months
8.4%
Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
---|---|---|---|---|---|---|---|---|
LARGE-CAP | ||||||||
AMGN | 117.9B | 26.2B | -7.64% | -12.03% | 14.89 | 4.5 | -0.48% | 38.34% |
GILD | 96.0B | 27.0B | -5.50% | 23.66% | 17.2 | 3.55 | -1.56% | 23.65% |
MRNA | 49.0B | 15.1B | -4.27% | -12.12% | 10.25 | 3.26 | -33.37% | -67.32% |
BIIB | 42.8B | 10.1B | -4.73% | 48.21% | 13.67 | 4.24 | -6.61% | 115.98% |
MID-CAP | ||||||||
NBIX | 8.7B | 1.6B | -13.93% | -4.24% | 136.39 | 5.46 | 32.38% | -10.36% |
DNLI | 4.1B | - | 17.13% | 24.41% | -11.15 | 38.1 | 122.90% | -29.67% |
BEAM | 2.4B | 76.7M | 3.81% | -9.32% | -7.51 | 30.96 | 41.73% | -32.75% |
BBIO | 2.2B | 107.9M | -4.32% | 100.88% | -4.54 | 20.39 | 54.84% | 17.36% |
SMALL-CAP | ||||||||
RCUS | 1.5B | 119.0M | 11.39% | 8.39% | -5.38 | 12.62 | -69.61% | -584.39% |
REPL | 1.1B | 10.0M | 8.51% | 30.70% | -6.18 | 107.56 | 215.65% | -47.65% |
NVAX | 694.6M | - | 4.27% | -85.45% | -0.6 | 0.35 | 72.89% | 12.32% |
FATE | 495.9M | 136.9M | -20.60% | -78.14% | -2.11 | 3.62 | 116.83% | -0.93% |
SGMO | 186.8M | 241.0M | -25.83% | -69.32% | -1.47 | 0.78 | 113.96% | 27.87% |
VXRT | 165.4M | 697.0K | 50.34% | -66.48% | -1.53 | 237.34 | 47.98% | -35.48% |
IBIO | 8.7M | - | -35.78% | -88.38% | -0.11 | 3.21 | 0.51% | -129.47% |
Income Statement (Last 12 Months) | (In Millions) | |||||
---|---|---|---|---|---|---|
Description | (%) Q/Q | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 |
Revenue | 6.2% | 119 | 112 | 433 | 409 | 392 |
Operating Expenses | 6.6% | 418 | 392 | 358 | 342 | 332 |
S&GA Expenses | 5.8% | 110 | 104 | 99.00 | 89.00 | 80.00 |
R&D Expenses | 6.9% | 308 | 288 | 258 | 253 | 252 |
EBITDA | -392.3% | -260 | 89.00 | 75.00 | -281 | - |
EBITDA Margin | -1230.1% | -2.32* | 0.21* | 0.18* | -0.72* | - |
Earnings Before Taxes | -4.1% | -277 | -266 | 83.00 | 70.00 | 61.00 |
EBT Margin | -1338.9% | -2.37* | 0.19* | 0.17* | -0.73* | - |
Net Income | -4.5% | -279 | -267 | 80.00 | 67.00 | 58.00 |
Net Income Margin | -1390.3% | -2.38* | 0.18* | 0.16* | 0.15* | - |
Free Cahsflow | 0.1% | 432 | 432 | 452 | 439 | - |
Balance Sheet | (In Millions) | |||||
---|---|---|---|---|---|---|
Description | (%) Q/Q | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 |
Assets | -6.8% | 1,254 | 1,345 | 1,394 | 1,477 | 1,543 |
Current Assets | -4.9% | 1,015 | 1,067 | 1,101 | 1,227 | 1,264 |
Cash Equivalents | 15.5% | 238 | 206 | 218 | 273 | 549 |
Net PPE | 5.7% | 37.00 | 35.00 | 34.00 | 33.00 | 33.00 |
Liabilities | -4.7% | 695 | 729 | 747 | - | - |
Current Liabilities | -7.3% | 179 | 193 | 177 | 164 | 161 |
Shareholder's Equity | -8.7% | 600 | 657 | 699 | 747 | 797 |
Retained Earnings | -14.8% | -622 | -542 | -474 | -409 | -343 |
Additional Paid-In Capital | 1.6% | 1,183 | 1,165 | 1,145 | - | - |
Shares Outstanding | 0.3% | 73.00 | 73.00 | 72.00 | 72.00 | 72.00 |
Cashflow (Last 12 Months) | (In Millions) | |||||
---|---|---|---|---|---|---|
Description | (%) Q/Q | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 |
Cashflow From Operations | -171.7% | -314 | 438 | 446 | 473 | 464 |
Share Based Compensation | 3.8% | 67.00 | 65.00 | 63.00 | 61.00 | 59.00 |
Cashflow From Investing | 96.1% | -15.94 | -413 | -441 | -553 | -334 |
Cashflow From Financing | -42.2% | 19.00 | 33.00 | 33.00 | 32.00 | 30.00 |
100%
100%
88.5%
Y-axis is the maximum loss one would have experienced if Arcus Biosciences was unfortunately bought at previous high price.
5.8%
-13.1%
FIve years rolling returns for Arcus Biosciences.
Datesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
---|---|---|---|---|---|---|
2023-05-23 | Capital Impact Advisors, LLC | added | 26.89 | 39,811 | 373,938 | 0.46% |
2023-05-22 | PUTNAM INVESTMENTS LLC | sold off | -100 | -2,722,130 | - | -% |
2023-05-22 | AMERIPRISE FINANCIAL INC | reduced | -4.44 | -664,562 | 3,557,440 | -% |
2023-05-19 | Coppell Advisory Solutions LLC | sold off | -100 | -4,136 | - | -% |
2023-05-18 | JPMORGAN CHASE & CO | added | 4.87 | -798,000 | 9,850,000 | -% |
2023-05-18 | NEW YORK STATE COMMON RETIREMENT FUND | reduced | -5.39 | -179,000 | 902,000 | -% |
2023-05-17 | VIRGINIA RETIREMENT SYSTEMS ET AL | added | 23.38 | -25,904 | 1,025,730 | 0.01% |
2023-05-17 | Thrivent Financial for Lutherans | reduced | -3.39 | -164,000 | 942,000 | -% |
2023-05-16 | Hudson Bay Capital Management LP | added | 359 | 3,153,900 | 4,187,900 | 0.02% |
2023-05-16 | Kiwi Wealth Investments Limited Partnership | unchanged | - | -135,198 | 1,010,660 | 0.07% |
Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
---|---|---|---|---|---|
Feb 14, 2023 | biotechnology value fund l p | 1.7% | 1,236,002 | SC 13G/A | |
Feb 14, 2023 | pfm health sciences, lp | 3.7% | 6 | SC 13G/A | |
Feb 09, 2023 | vanguard group inc | 6.04% | 4,373,177 | SC 13G | |
Jan 26, 2023 | blackrock inc. | 13.0% | 9,389,048 | SC 13G/A | |
Jan 20, 2023 | blackrock inc. | 13.0% | 9,389,048 | SC 13G/A | |
Oct 17, 2022 | pfm health sciences, lp | 5.5% | 6 | SC 13G | |
May 09, 2022 | blackrock inc. | 11.1% | 7,967,677 | SC 13G | |
Mar 14, 2022 | biotechnology value fund l p | 3.0% | 2,156,510 | SC 13G | |
Feb 14, 2022 | ecor1 capital, llc | 7.9% | 5,523,358 | SC 13G/A | |
Feb 14, 2022 | pfm health sciences, lp | 4.9% | 6 | SC 13G/A |
Date Filed | Form Type | Document | |
---|---|---|---|
May 15, 2023 | 8-K | Current Report | |
May 09, 2023 | 8-K | Current Report | |
May 09, 2023 | 10-Q | Quarterly Report | |
Apr 25, 2023 | ARS | ARS | |
Apr 21, 2023 | DEFA14A | DEFA14A | |
Apr 21, 2023 | DEF 14A | DEF 14A | |
Mar 20, 2023 | 4 | Insider Trading | |
Mar 10, 2023 | 8-K | Current Report | |
Mar 10, 2023 | 3 | Insider Trading | |
Feb 28, 2023 | S-8 | Employee Benefits Plan |
Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
---|---|---|---|---|---|---|
2023-03-16 | Jarrett Jennifer | sold | -146,734 | 16.81 | -8,729 | chief operating officer |
2023-01-27 | Jarrett Jennifer | sold | -37,632 | 23.52 | -1,600 | chief operating officer |
2023-01-26 | Jarrett Jennifer | sold | -7,068 | 23.56 | -300 | chief operating officer |
2023-01-23 | ROSEN TERRY J | acquired | - | - | 105,700 | chief executive officer |
2023-01-23 | Nuyten Dimitry SA | acquired | - | - | 34,000 | chief medical officer |
2023-01-23 | Goeltz II Robert C. | acquired | - | - | 34,000 | chief financial officer |
2023-01-23 | Jarrett Jennifer | acquired | - | - | 45,800 | chief operating officer |
2023-01-23 | Jaen Juan C. | acquired | - | - | 45,800 | president |
2023-01-23 | Tang Carolyn C. | acquired | - | - | 34,000 | general counsel |
2022-12-16 | Jaen Juan C. | sold | -136,407 | 30.7501 | -4,436 | president |
Condensed Consolidated Statements of Operations (unaudited) - USD ($) shares in Millions, $ in Millions | 3 Months Ended | |
---|---|---|
Mar. 31, 2023 | Mar. 31, 2022 | |
Revenues: | ||
Total revenues | $ 25 | $ 18 |
Operating expenses: | ||
Research and development (Net of recoveries of $33 and $30 from a related party) | 81 | 61 |
General and administrative | 30 | 24 |
Total operating expenses | 111 | 85 |
Loss from operations | (86) | (67) |
Non-operating income (expense): | ||
Interest and other income, net | 9 | |
Effective interest on liability for sale of future royalties | (1) | |
Total non-operating income, net | 8 | |
Loss before income taxes | (78) | (67) |
Income tax expense | (2) | (1) |
Net loss | $ (80) | $ (68) |
Net loss per share, basic | $ (1.09) | $ (0.96) |
Net loss per share, diluted | $ (1.09) | $ (0.96) |
Shares used to compute net income loss per share, basic | 73.0 | 71.2 |
Shares used to compute net income loss per share, diluted | 73.0 | 71.2 |
License and Development Services Revenue | ||
Revenues: | ||
Total revenues | $ 17 | $ 8 |
Other Collaboration Revenue | ||
Revenues: | ||
Total revenues | $ 8 | $ 10 |
Condensed Consolidated Balance Sheets - USD ($) $ in Millions | Mar. 31, 2023 | Dec. 31, 2022 |
---|---|---|
Current assets: | ||
Cash and cash equivalents | $ 238 | $ 206 |
Marketable securities | 716 | 803 |
Receivable from collaboration partners ($33 and $39 from a related party) | 33 | 39 |
Prepaid expenses and other current assets | 28 | 19 |
Total current assets | 1,015 | 1,067 |
Long-term marketable securities | 90 | 129 |
Property and equipment, net | 37 | 35 |
Other noncurrent assets ($3 and $2 from a related party) | 112 | 114 |
Total assets | 1,254 | 1,345 |
Current liabilities: | ||
Accounts payable | 28 | 20 |
Deferred revenue ($97 and $97 to a related party) | 97 | 97 |
Other current liabilities | 54 | 76 |
Total current liabilities | 179 | 193 |
Deferred revenue, noncurrent ($330 and $355 to a related party) | 330 | 355 |
Other noncurrent liabilities | 145 | 140 |
Commitments | ||
Stockholders’ equity: | ||
Preferred stock, $0.0001 par value per share; 10.0 shares authorized; no shares issued and outstanding | 0 | 0 |
Common stock and additional paid-in capital: $0.0001 par value per share; 400.0 shares authorized; 73.1 shares in 2023 and 72.9 shares in 2022 issued and outstanding | 1,226 | 1,206 |
Accumulated deficit | (622) | (542) |
Accumulated other comprehensive loss | (4) | (7) |
Total stockholders’ equity | 600 | 657 |
Total liabilities and stockholders’ equity | $ 1,254 | $ 1,345 |